+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Tuberculosis (TB)

  • ID: 4846148
  • Report
  • February 2021
  • Region: Global
  • 34 Pages
  • Pharma Intelligence
This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.

Key Takeaways
  • The publisher estimates that in 2018, there were 13.9 million incident cases of tuberculosis (TB) worldwide, and forecasts that number to increase to 15.3 million incident cases by 2027.
  • Approved drugs in the TB space focus on a variety of targets. The majority of these drugs are administered via the oral route, with the remainder being intradermal, topical, and intravenous formulations.
  • The largest proportion of industry-sponsored drugs in active clinical development for TB are in Phase II. Therapies in development for TB focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with two drugs being tested in an intramuscular formulation.
  • The only high-impact upcoming event for drugs in the TB space is topline Phase II trial results for GSK3036656. The overall likelihood of approval of a Phase I antibacterial, mycobacterial, or fungal asset is 19.8%, and the average probability a drug advances from Phase III is 62%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.0 years in the overall infectious disease space.
  • The distribution of clinical trials across Phase I–IV indicates that the majority of trials for TB have been in the early and midphases of development, with 74% of trials in Phase I–II, and only 26% in Phase III–IV.
  • South Africa has a substantial lead in the number of TB clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
  • Clinical trial activity in the TB space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for TB, with 17 trials.
  • GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for TB.
Note: Product cover images may vary from those shown

OVERVIEWKEY TAKEAWAYS
DISEASE BACKGROUND
  • Disease definition
  • Patient subtypes
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT
  • Anti-TB drugs
  • Surgery

EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGSKEY UPCOMING EVENTS
KEY REGULATORY EVENTS
  • The FDA’s Latest Nitrosamine Decision Weighs Tuberculosis Versus Cancer Risk
  • Hope For Price Flexibility After India Pretomanid Go-Ahead
  • Pediatric Approvals In TB, Bladder Dysfunction, And Atopic Dermatitis
  • Mylan Gets Expert Panel Go-Ahead For Pretomanid In India

PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
  • PerkinElmer Adds Infectious Disease Testing By Acquiring Oxford Immunotec For $591M
  • Amgen Licenses TB Candidate To MDGH

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY
  • Prescription information

APPENDIX
LIST OF FIGURES
Figure 1: Global trends in incident cases of tuberculosis, 2018–27
Figure 2: Overview of pipeline drugs for tuberculosis in the US
Figure 3: Pipeline drugs for tuberculosis, by company
Figure 4: Pipeline drugs for tuberculosis, by drug type
Figure 5: Pipeline drugs for tuberculosis, by classification
Figure 6: Key upcoming events in tuberculosis
Figure 7: Probability of success in the antibacterial, mycobacterial, or fungal pipeline
Figure 8: Clinical trials in tuberculosis
Figure 9: Top 10 drugs for clinical trials in tuberculosis
Figure 10: Top 10 companies for clinical trials in tuberculosis
Figure 11: Trial locations in tuberculosis
Figure 12: Tuberculosis trials status
Figure 13: Tuberculosis trials sponsors, by phase
LIST OF TABLES
Table 1: Global incident cases of tuberculosis, 2018–27
Table 2: Global incident cases of tuberculosis with HIV, 2018
Table 3: Global incident cases of MDR/RR tuberculosis, 2018
Table 4: Marketed drugs for tuberculosis
Table 5: Pipeline drugs for tuberculosis in the US
Note: Product cover images may vary from those shown